📟Preview
This presentation provides an overview of the relationship between ineffective erythropoiesis (IE) biomarkers and the development of extramedullary hematopoiesis (EMH) in thalassemia patients. IE, characterized by defective erythroid precursor cell production, is a critical mechanism in thalassemia-associated anemia.
- Identify the relationship between IE biomarkers (GDF15, sTfR, and PS-exposed RBCs) and the risk of developing EMH.
- Explore how these biomarkers reflect the severity of IE and its contribution to EMH development.
- Evaluate the potential of these biomarkers as diagnostic tools for predicting EMH in thalassemia patients.
We try to clarify some questions about ineffective erythropoiesis (IE) biomarkers, such as:
Reference:
- Chansai, Siriyakorn, et al. “The correlation between ineffective erythropoiesis biomarkers and development of extramedullary hematopoiesis in patients with thalassemia.” Mediterranean Journal of Hematology and Infectious Diseases 14.1 (2022)
- Rivella, Stefano. “Ineffective erythropoiesis and thalassemias.” Current opinion in hematology 16.3 (2009): 187
- Chansai, Siriyakorn, et al. “Phosphatidylserine-exposed red blood cells and ineffective erythropoiesis biomarkers in patients with thalassemia.” American Journal of Translational Research 14.7 (2022): 4743
- Nattiya Teawtrakul, M. D., et al. “A Clinical Risk Score for Predicting Paraspinal Extramedullary Hematopoiesis in Patients with Thalassemia: The KKU-EMH Score.” J Med Assoc Thai 100.4 (2017): 389-95
- Yang, Xinxin, et al. “The mechanisms of pathological extramedullary hematopoiesis in diseases.” Cellular and Molecular Life Sciences 77.14 (2020): 2723-2738
- Infusino, Ilenia, et al. “Soluble transferrin receptor (sTfR) and sTfR/log ferritin index for the diagnosis of iron-deficiency anemia a meta-analysis.” American journal of clinical pathology 138.5 (2012): 642-649